FY25 consensus $5.27. Narrows FY25 revenue view to $4.175B -$4.275B from $4.15B-$4.3B, consensus $4.22B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jazz Pharmaceuticals Appoints Dr. Ted Love to Board
- Jazz Pharmaceuticals Advances ONC201 Study for Glioma Treatment
- Jazz Pharmaceuticals’ ONC206 Study: A Potential Game-Changer in CNS Cancer Treatment
- Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan